All entries should refer to products, services and initiatives launched in between 30 June 2020 – 1 August 2021except from Excellence in Pharma: Finished Formulation - see criteria details for the eligibility period relevant to this category only.
Please click on the + icon to view the full criteria details for each category.
This award is designed to recognise innovation in technologies, products, processes, and services to combat the impact of COVID-19 on individuals, patients, healthcare professionals and communities. Including but not limited to the development and manufacture of potential vaccines, drug products and medical equipment and the introduction of services, solutions and resources to provide support to those effected by the pandemic.
Criteria
* Given the short timeframes for response to the COVID-19 pandemic, we understand that many products or solutions will not yet have regulatory approval. Please submit as much evidence and support for your entry as is feasibly possible.
Innovation in technologies, products, processes, and services for the development and manufacture of active pharmaceutical ingredients (APIs) including, but not limited to, synthesis, characterization, formulation, scale-up, software and database development, bulk manufacturing.
Criteria
Innovation in technologies, products, processes, and services related to the formulation of drug products including, but not limited to, excipients, finished dose, OTC, novel software and databases, process development, resolving formulation challenges such as solubility/ bioavailability enhancement, drug targeting or controlled release, solving stability issues such as protein aggregation, etc. Please note: to be eligible for this category, the activity must have taken place between Jan 2020 - August 2021
Criteria
Innovation in technologies, products, processes, and services for the manufacture of solid, semi-solid, parenteral, inhalation, or other dosage drugs including, but not limited to, equipment, manufacturing processes, facilities, process controls, and continuous manufacturing.
Criteria
Innovation in technologies, products, solutions, processes, and services related to primary, tertiary and secondary packaging of finished drug forms, routes of administration and drug delivery devices Including, but not limited to, inhalers, auto-injectors, vials, syringes, patches, combination products, tamper-proof packaging, child-safety packaging, labelling, intelligent packaging, and fill-finish.
Innovation in digital technologies, products, processes, initiatives, and services which drive value in pharmaceutical development and improve patient outcomes. Including but not limited to advanced and predictive analytics, Artificial Intelligence, automation, patient-centric solutions for improved experience and adherence, track and trace, remote monitoring, medical devices, and wearables.
Criteria
Innovation in technologies, products, processes, and services for ensuring the safe handling and tracking of drug substances, raw materials, and finished drug products including, but not limited to, supply chain, audits, temperature-controlled logistics, transport services, track and trace, shipping containers, and distribution channels.
Criteria
This award recognizes sustainable development in the Pharmaceutical industry and innovative initiatives for improving outcomes for patients, employees, the environment, and wider community. Including but not limited to, initiatives to minimize environmental impact, waste reduction, energy & utility saving solutions, sustainable and collaborative product development, innovative and sustainable use of resources, social outreach, employee training and mentoring programs, fair employee working policies, diversity and inclusion initiatives.
Criteria
Innovation in technologies, products, processes, and services designed to aid and ensure that bio/pharma companies comply with standards, rules, and guidance documents established by regulatory authorities including, but not limited to, consulting services, development of consortia and industry groups, reference standards, educational programs, and software and IT, technologies, and equipment.
Criteria
C-Suite Executives of SME, Large Pharma/Biopharma or service providers are eligible for nomination. Attributes to be considered include, but are not limited to, financial performance, product performance, global reach, leadership skills, management capability, charitable initiatives, sustainability, regulatory compliance, profitability, vision, marketing, acquisitions, corporate strategy, and financing.
Criteria
For entry and general enquiries:
Natalia Kay
Tel: +44 (0) 7917 265 637
Email: natalia.kay@informa.com
For Sponsorship enquiries:
Christopher Keeling
Tel: +44 (0) 7917 647 859
Email: christopher.keeling@informa.com